Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMETER Trial: Dexamethasone as an Adjunct to Endocrine Therapy in ER+, HER2- Metastatic Breast Cancer
NCT07786051Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2026
- Primary completion
- Nov 2028
01
Overview
Phase 2, open-label trial of dexamethasone in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical Benefit Rate at 16 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07786051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786051.